David S Snyder
Overview
Explore the profile of David S Snyder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1825
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ali H, Tsai N, Synold T, Mokhtari S, Tsia W, Palmer J, et al.
Blood Adv
. 2021 Sep;
6(5):1444-1453.
PMID: 34581764
We report results of our prospective pilot trial evaluating safety/feasibility of peritransplantation ruxolitinib for myelofibrosis treatment. Primary objectives were to determine safety and maximum tolerated dose (MTD) of ruxolitinib. Ruxolitinib...
2.
Salhotra A, Aribi A, Ngo D, Zhang J, Sandhu K, Al-Malki M, et al.
Am J Hematol
. 2021 Mar;
96(6):E196-E200.
PMID: 33719090
No abstract available.
3.
Deininger M, Shah N, Altman J, Berman E, Bhatia R, Bhatnagar B, et al.
J Natl Compr Canc Netw
. 2020 Oct;
18(10):1385-1415.
PMID: 33022644
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a...
4.
Gerds A, Gotlib J, Bose P, Deininger M, Dunbar A, Elshoury A, et al.
J Natl Compr Canc Netw
. 2020 Sep;
18(9):1248-1269.
PMID: 32886902
Eosinophilic disorders and related syndromes represent a heterogeneous group of neoplastic and nonneoplastic conditions, characterized by more eosinophils in the peripheral blood, and may involve eosinophil-induced organ damage. In the...
5.
Oppliger Leibundgut E, Haubitz M, Burington B, Ottmann O, Spitzer G, Odenike O, et al.
Haematologica
. 2020 Aug;
106(9):2397-2404.
PMID: 32732354
In a phase-2 study, the telomerase inhibitor imetelstat induced rapid hematologic responses in all patients with essential thrombocythemia who were refractory or intolerant to prior therapies. Significant molecular responses were...
6.
Dulan S, Viers K, Wagner J, Clark M, Chang B, Gorospe G, et al.
Biol Blood Marrow Transplant
. 2020 May;
26(8):1386-1393.
PMID: 32439475
As the world of cellular therapy expands to include immune effector cell (IEC) products such as commercial chimeric antigen receptor (CAR) T cells, quality management (QM) professionals are faced with...
7.
Wu J, Chen Y, Hageman L, Francisco L, Ness E, Parman M, et al.
Cancer
. 2019 Aug;
125(22):4033-4042.
PMID: 31412155
Background: Late mortality was investigated in patients with chronic myelogenous leukemia (CML) who underwent blood or bone marrow transplant (BMT) with or without prior tyrosine kinase inhibitor (TKI) therapy. Methods:...
8.
Dickter J, Cai L, Snyder D
Case Rep Infect Dis
. 2019 Apr;
2019:5464230.
PMID: 31032127
A 69-year-old immunocompromised man developed mitral valve endocarditis due to serotype Mbandaka, contracted from the cereal outbreak. The patient had a history of HLA-matched related hematopoietic stem cell transplant with...
9.
Gotlib J, Gerds A, Bose P, Castells M, Deininger M, Gojo I, et al.
J Natl Compr Canc Netw
. 2018 Dec;
16(12):1500-1537.
PMID: 30545997
Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is...
10.
Radich J, Deininger M, Abboud C, Altman J, Berman E, Bhatia R, et al.
J Natl Compr Canc Netw
. 2018 Sep;
16(9):1108-1135.
PMID: 30181422
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1...